Stock 000590 TUS-PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tus-Pharmaceutical Group Co., Ltd.

Equities

000590

CNE000000701

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-03 EDT 		5-day change 1st Jan Change
5.87 CNY -1.18% Intraday chart for Tus-Pharmaceutical Group Co., Ltd. -14.56% -34.49%
04-25 Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-27 Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,820 2,864 2,031 2,366 2,141 2,146
Enterprise Value (EV) 1 1,537 2,550 1,693 2,053 2,014 2,051
P/E ratio -47.7 x 67.5 x 89.4 x 66.8 x 118 x 85 x
Yield - - - - - -
Capitalization / Revenue 9.79 x 9.09 x 7.38 x 7.87 x 6.11 x 5.3 x
EV / Revenue 8.27 x 8.09 x 6.15 x 6.83 x 5.75 x 5.07 x
EV / EBITDA -57.3 x 65.3 x 51.2 x 48.1 x 60.2 x 52 x
EV / FCF -42.6 x 190 x 249 x -73.4 x 92.4 x -31.9 x
FCF Yield -2.35% 0.53% 0.4% -1.36% 1.08% -3.14%
Price to Book 3.14 x 4.6 x 3.15 x 3.48 x 3.07 x 2.96 x
Nbr of stocks (in thousands) 239,471 239,471 239,471 239,471 239,471 239,471
Reference price 2 7.600 11.96 8.480 9.880 8.940 8.960
Announcement Date 4/19/19 4/8/20 3/29/21 3/30/22 3/27/23 3/27/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 185.8 315 275.1 300.8 350.5 404.6
EBITDA 1 -26.82 39.06 33.06 42.69 33.46 39.42
EBIT 1 -42.81 24.83 18.96 25.97 12.13 14.3
Operating Margin -23.04% 7.88% 6.89% 8.63% 3.46% 3.53%
Earnings before Tax (EBT) 1 -35.9 53.44 27.64 41.84 21.88 29.68
Net income 1 -38.18 42.44 22.72 35.44 18.15 25.25
Net margin -20.55% 13.47% 8.26% 11.78% 5.18% 6.24%
EPS 2 -0.1594 0.1772 0.0949 0.1480 0.0758 0.1054
Free Cash Flow 1 -36.1 13.43 6.809 -27.96 21.79 -64.34
FCF margin -19.43% 4.26% 2.48% -9.3% 6.22% -15.9%
FCF Conversion (EBITDA) - 34.39% 20.6% - 65.14% -
FCF Conversion (Net income) - 31.65% 29.97% - 120.11% -
Dividend per Share - - - - - -
Announcement Date 4/19/19 4/8/20 3/29/21 3/30/22 3/27/23 3/27/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 283 314 338 313 127 94.3
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -36.1 13.4 6.81 -28 21.8 -64.3
ROE (net income / shareholders' equity) -6.57% 7.06% 3.59% 5.34% 2.62% 3.48%
ROA (Net income/ Total Assets) -3.17% 1.87% 1.36% 1.75% 0.71% 0.77%
Assets 1 1,206 2,275 1,667 2,031 2,555 3,275
Book Value Per Share 2 2.420 2.600 2.690 2.840 2.920 3.020
Cash Flow per Share 2 1.340 1.310 1.430 1.050 0.9800 0.7900
Capex 1 22.6 35.8 33.9 25.9 18.7 22
Capex / Sales 12.16% 11.38% 12.33% 8.6% 5.33% 5.45%
Announcement Date 4/19/19 4/8/20 3/29/21 3/30/22 3/27/23 3/27/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TUS-PHARMACEUTICAL GROUP CO., LTD. Stock Tus-Pharmaceutical Group Co., Ltd.
-34.49% 196M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.83% 748B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.70% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.06% 325B
ABBVIE INC. Stock AbbVie Inc.
+4.63% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 245B
NOVARTIS AG Stock Novartis AG
+9.26% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-4.21% 209B
PFIZER, INC. Stock Pfizer, Inc.
+2.43% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 000590 Stock
  4. Financials Tus-Pharmaceutical Group Co., Ltd.